Received a live vaccine within 30 days of the first dose of study medication
Administration of a live vaccine within 30 days prior to first dose of study drug
Received a live vaccine within 30 days prior to first dose of study drug
Has received a live vaccine within 30 days prior to the first dose of study therapy
Has received a live-virus vaccine within 30 days prior to first dose of study medication.
Has received a live vaccine within 30 days prior to the first dose of study therapy
Have received a live vaccine within 30 days before the first dose of study treatment.
Has received a live vaccine within 30 days prior to first dose of study drug.
Received a vaccine within 7 days of first dose
Received a live vaccine within 30 days of the first dose of treatment.
Has received a live attenuated vaccine within 28 days before the first dose of study drug
Has received a live vaccine within 30 days prior to the first dose of study drug
Has received a live vaccine within 30 days prior to the first dose of study treatment.
Patients who have received live, attenuated vaccine within 28 days prior to the first dose of PD-1 inhibitor.
Has received a live vaccine within 30 days prior to the first dose of study drug
Has received a live vaccine within 30 days prior to first dose
Patients who have received a live vaccine within 30 days prior to the first dose of pembrolizumab
Has received a live attenuated vaccine within 28 days before the first dose of study drug
Subjects must not have received a live vaccine within 30 days prior to the first dose of study medication
Have received a live vaccine within 30 days before the first dose of study treatment.
Has received a live vaccine within 30 days prior to the first dose of study drug
Received a live vaccine within 30 days prior to first dose of study drug
Patient has received a live vaccine within 4 weeks prior to the first dose of treatment
Have received any live vaccine within 14 days prior to first study drug administration.
Received a live attenuated vaccine within 28 days of first study dose, unable to take oral medications
Has received a live vaccine within 30 days prior to the first dose of study treatment
Received a live vaccine within 30 days prior to the first dose of study treatment.
Patient has received a live vaccine within 30 days prior to first dose
Received a live vaccine within 1 week prior to the first dose of study treatment
Has received a live vaccine within 30 days of the first dose of study therapy
Has received a live vaccine within 30 days prior to first dose of study drug.
Received a live vaccine within 30 days prior to the first dose of study medication
Live vaccine use within 30 days of first dose of study medication.
Has taken any prohibited medications that are listed in the protocol within 14 days of the first dose of study treatment. Subject has received or will receive a live vaccine within 30 days before the first administration of study treatment
Has received a live vaccine within 30 days prior to first dose.
Received or will receive a live vaccine within 30 days prior to first dose of study drug
Received a live vaccine within 30 days prior to first dose of study drug
Received a live vaccine within 30 days of the first dose of study medication
Treatment with live vaccine within 30 days prior to the first dose of study medication are not eligible
Has received a live vaccine within 30 days prior to the first dose of study drug
Has received a live vaccine within 30 days prior to the first dose of study drug
Has received a live vaccine within 30 days prior to the first dose of study treatment
Has received a live vaccine within 30 days prior to the first dose of study treatment
Has received a live vaccine within 30 days of the first dose of study treatment.
Has received a live vaccine within 30 days prior to first dose of study therapy
Have received a live vaccine within 30 days before the first dose of study treatment
Received live, attenuated vaccine within 28 days prior to the first dose of mogamulizumab;
Has received a live vaccine within 30 days prior to first dose
Has received a live vaccine within 30 days prior to the first dose of study therapy
Has received a live vaccine within 30 days prior to the first dose of study treatment
Has received a live vaccine within 30 days prior to the first dose of study treatment.
Has received a live-virus vaccine within 30 days prior to the first dose of study treatment
Received a live viral vaccine within 6 months prior to the first dose of study drug.
Has received a live vaccine within 30 days prior to first dose of study drug.
